Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
May 02 2023 - 8:47AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the
"Company"), a biotechnology company developing therapeutic
candidates targeting drug resistant and devastating cancers, using
proprietary ferroptosis with immuno-oncology targeted novel
biologics, today announced that its Founder and CEO Randy Milby
will be presenting at the following industry and financial investor
conferences:
Event: 12th Drug Discovery Strategic
Summit 2023Date: May 3-4
2023Location: Boston,
MARegistration: Link
Event: Sidoti Micro-Cap Virtual
ConferenceDate: May 10-11,
2023Registration: LinkWebcast:
Link
Event: World Orphan Drug
CongressDate: May 23-25,
2023Location: Gaylord National Resort and
Convention Center in Washington, D.C.Registration:
Link
“We look forward to attending May’s prestigious events and
proudly showcasing our lead drug candidate, HSB-1216, to
scientists, investors, and clinicians from the global scientific
and financial community,” said Randy Milby, Hillstream BioPharma’s
Founder and CEO. “Our novel ferroptosis mechanism combined with our
next generation QuatramerTM tumor targeting platform offers
tremendous potential for treating drug-resistant devastating
cancers, and we look forward to communicating our innovative
scientific research and therapeutic drug development as well as the
value proposition of our business.
“We continue to advance HSB-1216 and HSB-3215 through
pre-clinical studies in our lab. Having recently engaged OncoBay
Clinical as a clinical research organization (CRO), we are readying
HSB-1216 for its planned IND filing with the FDA later this year,”
he added.
To schedule a meeting with the management team at any of the
following events, please email
investorrelations@hillstreambio.com.
About Hillstream BioPharma, Inc.
Hillstream BioPharma, Inc. is a biotechnology company developing
a focused portfolio of therapeutic candidates targeting drug
resistant and devastating cancers. The Company anticipates
submitting an investigational new drug application and plans to
initiate a clinical study in the second half of 2023 with HSB-1216,
which targets ferroptosis -- an emerging new anti-cancer mechanism
resulting in iron mediated cell death (IMCD) of drug resistant
cancers. The Company’s emerging immuno-oncology pipeline is led by
HSB-3215, a novel anti-HER2 monoclonal antibody targeting unique
epitopes with a novel mechanism of action. The erbB/HER family of
cell surface proteins include well-known and validated drug targets
including HER2 and HER3 found in multiple solid tumors, including
breast, lung, GYN, endocrinological and CNS. For more information,
please visit: www.hillstreambio.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified using words such as
“anticipate,” “believe,” “forecast,” “estimated” and “intend” or
other similar terms or expressions that concern Hillstream’s
expectations, strategy, plans or intentions. These forward-looking
statements are based on Hillstream’s current expectations and
actual results could differ materially. There are several factors
that could cause actual events to differ materially from those
indicated by such forward-looking statements. These factors
include, but are not limited to, clinical trials involve a lengthy
and expensive process with an uncertain outcome, and results of
earlier studies and trials may not be predictive of future trial
results; our clinical trials may be suspended or discontinued due
to unexpected side effects or other safety risks that could
preclude approval of our product candidates; risks related to
business interruptions, including the outbreak of COVID-19
coronavirus, which could seriously harm our financial condition and
increase our costs and expenses; dependence on key personnel;
substantial competition; uncertainties of patent protection and
litigation; dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. Investors should read the risk factors set
forth in our Form 10-K for the year ended December 31, 2022 and our
periodic reports filed with the Securities and Exchange Commission.
While the list of factors presented here is considered
representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted
factors may present significant additional obstacles to the
realization of forward-looking statements. Forward-looking
statements included herein are made as of the date hereof, and
Hillstream does not undertake any obligation to update publicly
such statements to reflect subsequent events or circumstances.
Investor Relations Contact
Email: investorrelations@hillstreambio.com
www.hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Apr 2023 to Apr 2024